---
title: "CytomX Therapeutics, Inc. (CTMX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CTMX.US.md"
symbol: "CTMX.US"
name: "CytomX Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-04-15T02:25:30.677Z"
locales:
  - [en](https://longbridge.com/en/quote/CTMX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CTMX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CTMX.US.md)
---

# CytomX Therapeutics, Inc. (CTMX.US)

## Company Overview

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.cytomx.com](https://www.cytomx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-14T04:30:17.000Z

**Overall: C (0.55)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 125 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -44.82% |  |
| Net Profit YoY | -163.92% |  |
| P/B Ratio | 9.59 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 949018386.51 |  |
| Revenue | 76201000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -41.34% | E |
| Profit Margin | -22.79% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | -44.82% | E |
| Net Profit YoY | -163.92% | E |
| Total Assets YoY | 25.75% | A |
| Net Assets YoY | 21812.28% | A |
| Cash Flow Margin | 371.07% | A |
| OCF YoY | -44.82% | E |
| Turnover | 0.56 | B |
| Gearing Ratio | 34.68% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - CytomX Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-44.82%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-163.92%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "9.59",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "949018386.51",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "76201000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-41.34%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-22.79%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-44.82%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-163.92%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "25.75%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "21812.28%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "371.07%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-44.82%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.56",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "34.68%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -48.18 | 538/393 | 25.94 | 11.00 | 7.25 |
| PB | 9.91 | 387/393 | 13.77 | 7.66 | 4.61 |
| PS (TTM) | 12.88 | 181/393 | 7.86 | 3.89 | 2.38 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | C | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-30T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 67% |
| Overweight | 3 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.54 |
| Highest Target | 17.00 |
| Lowest Target | 11.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CTMX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CTMX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CTMX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CTMX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**